In another pooled analysis of two randomized trials, UFT showed a similar therapeutic impact on recurrence-free survival and overall survival compared with classical cyclophosphamide, methotrexate, and fluorouracil (CMF) for early breast cancer patients with ER-positive and high-risk node-negative or node-positive disease [10–12]. Here, ESR1 is linked to breast carcinoma.